Active not recruiting × Thyroid Neoplasms × Sarcoma × Clear all
NCT02834013 2026-04-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 4 FDA
NCT04284774 2025-12-04

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
155 enrolled
NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled